Skip to main content

Drug Interactions between Andro-Cyp 200 and telithromycin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

testosterone telithromycin

Applies to: Andro-Cyp 200 (testosterone) and telithromycin

MONITOR: Coadministration with telithromycin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telithromycin.

MANAGEMENT: Caution is advised if telithromycin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telithromycin is added to or withdrawn from therapy.

References

  1. (2004) "Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals
  2. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (2004) European Public Assessment Report Ketek (telithromycin) (Rev. 2) http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.